Company Overview and News

DoT to issue notice to five telcos to recover Rs 2,578 cr

2017-12-31 moneycontrol
The Department of Telecom (DoT) will issue notice to five telecom operators, including Tata Teleservices, Telenor and Reliance Jio, to recover Rs 2,578 crore, in the wake of the CAG red-flagging understatement of revenues by the firms.

Tata Tele, Telenor, 3 others understated revenue by Rs 14,000 crore

2017-12-19 moneycontrol
Tata Teleservices, Telenor, Videocon and Reliance Jio are among five telecom firms which have understated revenues by over Rs 14,800 crore, resulting in a shortfall of nearly Rs 2,578 crore to the exchequer, government auditor CAG said today.

Five telecom firms understated AGR by Rs 14,800 cr: CAG

2017-12-19 business-standard
Tata Teleservices, Telenor, Videocon Telecom, Quadrant Televentures, and Reliance Jio Infocomm have understated their adjusted gross revenue (AGR) by over Rs 14,800 crore, which has resulted in a shortfall of Rs 1,526.70 crore to the government, according to a report by the Comptroller and Auditor General (CAG) of India.   The report, tabled in Parliament, states the interest on the short payment stood at Rs 1,052.

Quadrant Televentures reports standalone net loss of Rs 48.10 crore in the March 2017 quarter

2017-06-23 indiainfoline
For the full year,net loss reported to Rs 152.08 crore in the year ended March 2017 as against net loss of Rs 134.81 crore during the previous year ended March 2016. Sales declined 5.48% to Rs 527.79 crore in the year ended March 2017 as against Rs 558.37 crore during the previous year ended March 2016.

Videocon’s six-fold losses spell trouble for the debt-ridden conglomerate

2017-02-13 livemint
Videocon Industries increaseed their year-long loss to Rs1,367.94 crore—a whopping 24 times higher than the previous year

India’s Mobile-Phone Price War Seen Spurring Consolidation - Bloomberg

2017-01-27 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company News

2017-01-20 thehindubusinessline
Hindustan Construction Co on Friday said it has allotted 4.155 crore shares and 23.2 lakh optionally-convertible debentures to lenders, under a debt restructuring scheme. The company has allotted 1.586 crore shares to Axis Bank, 2.196 crore shares to Punjab National Bank and 37.3 lakh shares to Standard Chartered Bank. It also allotted 9.74 lakh convertible debentures to Axis Bank and 13.5 lakh CDs to PNB.

Videocon Telecom to shut Punjab circle ops from February 15

2017-01-20 moneycontrol
Ensure that your correct email id and mobile has been registered with moneycontrol. If not, please update your profile and secure the account now. Updating your email id and mobile number offers following benefits:

Quadrant Televentures reports standalone net loss of Rs 14.89 crore in the March 2016 quarter

2016-05-28 indiainfoline
We encourage visitors to register on IIFL. Registering on the site is absolutely Free and offers you the following benefits.


Related Articles

ACIA: Acacia Communications Analysis and Research Report

7m - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...